PubMed · 2019 · 11 citations · 7 references
PharmacyOncologySurgeryCancer Drug Toxicity ManagementHepatic PharmacotherapyOncology Medication SafetyHepatocellular Carcinoma PharmacotherapySteroid PharmacologyThromboembolism PreventionAcute Adverse EventsCochran's Q TestCochran-mantel-haenszel TestControl Group DesignMatched Control GroupSerious Adverse EventsSteroid Adverse EffectsSteroid Dose Response
Steroids are often administered at the time of transcatheter arterial chemoembolization (TACE), a standard treatment of hepatocellular carcinoma (HCC), with the expectation of preventing postembolization syndrome. Here we investigated the precise effects of steroids on TACE. We prospectively enrolled 144 HCC patients from 10 hospitals who underwent TACE. Three hospitals used steroids (steroid group, n=77) and the rest did not routinely use steroids (control group, n=67). The occurrence of adverse events and the algetic degree at 1-5 days post-treatment were compared between the groups. Fever (grades 0-2) after TACE was significantly less in the steroid group (56/21/0) compared to the control group (35/29/3, p=0.005, Cochran-Armitage test for trend). The suppressive effect of steroids against fever was prominent in females (p=0.001). Vomiting (G0/G1/ G2-) was also less frequent in the steroid group (70/5/2) versus the control group (53/10/3), but not significantly (p=0.106). The algetic degree and the grade of hematological adverse events, including hyperglycemia, did not differ between the groups. We conclude that the administration of steroids was useful for the prevention of adverse events after TACE in patients with HCC.
7
Management of Hepatocellular Carcinoma: An Update Δσ
Jordi Bruix, Morris Sherman · Hepatology · 2011 · 8.1K citations · Full text
Josep M. Llovet, Michel Ducreux, Riccardo Lencioni et al. · 2012 · 1.5K citations
Antiemetic Efficacy of Dexamethasone
Maurie Markman, Vivian R. Sheidler, David S. Ettinger et al. · New England Journal of Medicine · 1984 · 178 citations
Jean Latreille, Joseph L. Pater, D. Johnston et al. · Journal of Clinical Oncology · 1998 · 117 citations
Medicine, Oncology, Pharmacology +16
National Cancer Institute of Canada Clinical Trials Group
Annals of Oncology · 1994 · 50 citations · Full text